U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H30O3
Molecular Weight 342.4718
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MEGESTROL

SMILES

CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C

InChI

InChIKey=VXIMPSPISRVBPZ-NWUMPJBXSA-N
InChI=1S/C22H30O3/c1-13-11-16-17(20(3)8-5-15(24)12-19(13)20)6-9-21(4)18(16)7-10-22(21,25)14(2)23/h11-12,16-18,25H,5-10H2,1-4H3/t16-,17+,18+,20-,21+,22+/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/?term=23395103

Megestrol acetate is a progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer. MEGACE Oral Suspension is indicated for the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS). The precise mechanism by which megestrol acetate produces effects in anorexia and cachexia is unknown at the present time. But its progestin antitumour activity may involve suppression of luteinizing hormone by inhibition of pituitary function. Studies also suggest that the megestrol's weight gain effect is related to its appetite-stimulant or metabolic effects rather than its glucocorticoid-like effects or the production of edema. It has also been suggested that megestrol may alter metabolic pathyways via interferences with the production or action of mediators such as cachectin, a hormone that inhibits adipocyte lipogenic enzymes. The major route of drug elimination in humans is urine. When radiolabeled megestrol acetate was administered to humans in doses of 4 to 90 mg, the urinary excretion within 10 days ranged from 56.5% to 78.4% (mean 66.4%) and fecal excretion ranged from 7.7% to 30.3% (mean 19.8%). The total recovered radioactivity varied between 83.1% and 94.7% (mean 86.2%). Megestrol acetate metabolites which were identified in urine constituted 5% to 8% of the dose administered. Respiratory excretion as labeled carbon dioxide and fat storage may have accounted for at least part of the radioactivity not found in urine and feces. Plasma steady-state pharmacokinetics of megestrol acetate were evaluated in 10 adult, cachectic male patients with acquired immunodeficiency syndrome (AIDS) and an involuntary weight loss greater than 10% of baseline. Patients received single oral doses of 800 mg/day of MEGACE Oral Suspension for 21 days. Plasma concentration data obtained on day 21 were evaluated for up to 48 hours past the last dose.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
MEGACE

Approved Use

Megestrol acetate oral suspension is indicated for the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS).

Launch Date

1993
Palliative
MEGACE

Approved Use

Megestrol acetate oral suspension is indicated for the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS).

Launch Date

1993
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1364 ng/mL
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEGESTROL ACETATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
1616 ng/mL
675 mg single, oral
dose: 675 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEGESTROL ACETATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
187 ng/mL
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEGESTROL ACETATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
1044 ng/mL
675 mg single, oral
dose: 675 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEGESTROL ACETATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
1618 ng/mL
625 mg single, oral
dose: 625 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEGESTROL ACETATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
1133 ng/mL
625 mg single, oral
dose: 625 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEGESTROL ACETATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1364 ng/mL
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEGESTROL ACETATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
187 ng/mL
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEGESTROL ACETATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
753 ng/mL
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
MEGESTROL ACETATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
490 ng/mL
750 mg 1 times / day steady-state, oral
dose: 750 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
MEGESTROL ACETATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
18625 ng × h/mL
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEGESTROL ACETATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
17029 ng × h/mL
675 mg single, oral
dose: 675 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEGESTROL ACETATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
8942 ng × h/mL
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEGESTROL ACETATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
11879 ng × h/mL
675 mg single, oral
dose: 675 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEGESTROL ACETATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
16268 ng × h/mL
625 mg single, oral
dose: 625 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEGESTROL ACETATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
12095 ng × h/mL
625 mg single, oral
dose: 625 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEGESTROL ACETATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
18625 ng × h/mL
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEGESTROL ACETATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
8942 ng × h/mL
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEGESTROL ACETATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
10476 ng × h/mL
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
MEGESTROL ACETATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
6779 ng × h/mL
750 mg 1 times / day steady-state, oral
dose: 750 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
MEGESTROL ACETATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
39.75 h
625 mg single, oral
dose: 625 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEGESTROL ACETATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
33.68 h
625 mg single, oral
dose: 625 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEGESTROL ACETATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
32.84 h
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEGESTROL ACETATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
31.38 h
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEGESTROL ACETATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
400 mg 2 times / day multiple, oral
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, 54-68 years
Health Status: unhealthy
Age Group: 54-68 years
Sex: F
Sources:
Disc. AE: Osteoporosis...
AEs leading to
discontinuation/dose reduction:
Osteoporosis (2 patients)
Sources:
625 mg 1 times / day multiple, oral
Recommended
Dose: 625 mg, 1 times / day
Route: oral
Route: multiple
Dose: 625 mg, 1 times / day
Sources:
unhealthy, 65 years
Health Status: unhealthy
Age Group: 65 years
Sex: M
Sources:
Disc. AE: Adrenal insufficiency...
AEs leading to
discontinuation/dose reduction:
Adrenal insufficiency (1 patient)
Sources:
40 mg 2 times / day multiple, oral
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, 85 years
Health Status: unhealthy
Age Group: 85 years
Sex: F
Sources:
Disc. AE: Deep vein thrombosis...
AEs leading to
discontinuation/dose reduction:
Deep vein thrombosis (1 patient)
Sources:
400 mg 2 times / day multiple, oral
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, 86 years
Health Status: unhealthy
Age Group: 86 years
Sex: F
Sources:
Disc. AE: Deep vein thrombosis...
AEs leading to
discontinuation/dose reduction:
Deep vein thrombosis (1 patient)
Sources:
1600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sex: F
Sources:
AEs

AEs

AESignificanceDosePopulation
Osteoporosis 2 patients
Disc. AE
400 mg 2 times / day multiple, oral
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, 54-68 years
Health Status: unhealthy
Age Group: 54-68 years
Sex: F
Sources:
Adrenal insufficiency 1 patient
Disc. AE
625 mg 1 times / day multiple, oral
Recommended
Dose: 625 mg, 1 times / day
Route: oral
Route: multiple
Dose: 625 mg, 1 times / day
Sources:
unhealthy, 65 years
Health Status: unhealthy
Age Group: 65 years
Sex: M
Sources:
Deep vein thrombosis 1 patient
Disc. AE
40 mg 2 times / day multiple, oral
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, 85 years
Health Status: unhealthy
Age Group: 85 years
Sex: F
Sources:
Deep vein thrombosis 1 patient
Disc. AE
400 mg 2 times / day multiple, oral
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, 86 years
Health Status: unhealthy
Age Group: 86 years
Sex: F
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
mild [Inhibition 50 uM]
mild [Inhibition 50 uM]
moderate [Inhibition 50 uM]
moderate [Inhibition 50 uM]
no
no
no
yes [Activation 50 uM]
yes [Activation 50 uM]
yes [Inhibition 50 uM]
Drug as victim
PubMed

PubMed

TitleDatePubMed
Managing cancer-related anorexia/cachexia.
2001
Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma.
2001 Feb 1
Estrogen as therapy for breast cancer.
2002
Cost-effectiveness analysis of exemestane compared with megestrol in advanced breast cancer: a model for Europe and Australia.
2002
Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis.
2002 Apr
Effect of megestrol caproate on the reproductive function of laboratory animals.
2002 Jun
[Reversal of nomegestrol acetate on multidrug resistance in drug-resistant human breast cancer cell line MCF7/ADR].
2002 Mar
Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
2002 Mar
Effects of transdermal hormone replacement therapy on levels of soluble P- and E-selectin in postmenopausal healthy women.
2002 Mar
Acute effects of megestrol on the hypothalamic-pituitary-adrenal axis.
2003 Dec
Megestrol complications.
2003 Jan
Postmenopausal femur bone loss: effects of a low dose hormone replacement therapy.
2003 Jul 25
[Effects of a 19-norprogesterone derivative, the fourth decade nomegestrol acetate, on lipids].
2003 Jun
[Comparison of changes in biochemical markers of bone turnover after 6 months of hormone replacement therapy with either transdermal 17 beta-estradiol or equine conjugated estrogen plus nomegestrol acetate].
2003 May
An overview of nomegestrol acetate selective receptor binding and lack of estrogenic action on hormone-dependent cancer cells.
2003 Nov
Incidence of deep-venous thrombosis in nursing home residents using megestrol acetate.
2003 Sep-Oct
Nomegestrol acetate: a progestin that deserves recognition.
2004 Apr
The role of MRI in the conservative management of endometrial cancer.
2004 Apr
[Nome gesrol (lutenyl) induced severe acute hepatitis].
2004 Jan
Serum leptin levels and body composition in postmenopausal women: effects of hormone therapy.
2004 Jul-Aug
Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-II: systemic and local non-embolization-based therapies in unresectable and advanced hepatocellular carcinoma.
2004 Jun
Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?
2004 May 4
Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
2005
Treatment with inhibitors of angiogenesis in advanced hepatocellular carcinoma: a new tool in our hands or simply a hope?
2005 Apr
The effects of aromatase inhibitors on lipids and thrombosis.
2005 Aug
[Actions of a 19-norprogesterone derivative on mammary gland: nomegestrol acetate].
2005 Feb
Effect of nomegestrol acetate on estrogen biosynthesis and transformation in MCF-7 and T47-D breast cancer cells.
2005 Jan
Pregnancy following intracytoplasmic sperm injection and preimplantation genetic diagnosis after the conservative management of endometrial cancer.
2005 Jun
Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer.
2005 May 9
The role of aromatase inhibitors in ameliorating deleterious effects of ovarian stimulation on outcome of infertility treatment.
2005 Oct 4
Review of cost-effectiveness analyses in hormonal therapies in advanced breast cancer.
2005 Sep
Progestogens: effects on clinical and biochemical parameters in postmenopausal women.
2005 Sep-Oct
Durable response of metastatic endometrial carcinoma to treatment with fulvestrant (Faslodex) after prior progestin and anastrozole therapy.
2006 Feb
Short-term progestin treatments prevent estrous induction by a GnRH agonist implant in anestrous bitches.
2006 Jan 20
Activation of nitric oxide synthesis in human endothelial cells using nomegestrol acetate.
2006 Oct
Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: a randomized, double-blind, placebo-controlled, multicenter trial.
2007 Feb
Longitudinal evaluation of serum leptin and bone mineral density in early postmenopausal women.
2007 May-Jun
Patents

Patents

Sample Use Guides

Oral Suspension is 800 mg/day (20 mL/day). In clinical trials evaluating different dose schedules, daily doses of 400 and 800 mg/day.
Route of Administration: Oral
Megestrol acetate was shown to inhibit the growth of HepG2 cells in vitro in dose- and time-dependent manners with an IC (50) of 260 uM (24-h incubation)
Name Type Language
CHRONOPIL
Preferred Name English
MEGESTROL
HSDB   INN   VANDF   WHO-DD  
INN  
Official Name English
MEGESTROL ACETATE IMPURITY B [EP IMPURITY]
Common Name English
MEGESTROL [VANDF]
Common Name English
MEGESTROL [HSDB]
Common Name English
Megestrol [WHO-DD]
Common Name English
17-HYDROXY-6-METHYLPREGNA-4,6-DIENE-3,20-DIONE
Systematic Name English
megestrol [INN]
Common Name English
Classification Tree Code System Code
WHO-VATC QG03AC05
Created by admin on Mon Mar 31 17:33:23 GMT 2025 , Edited by admin on Mon Mar 31 17:33:23 GMT 2025
WHO-ATC G03AC05
Created by admin on Mon Mar 31 17:33:23 GMT 2025 , Edited by admin on Mon Mar 31 17:33:23 GMT 2025
LIVERTOX 593
Created by admin on Mon Mar 31 17:33:23 GMT 2025 , Edited by admin on Mon Mar 31 17:33:23 GMT 2025
WHO-ATC G03FB04
Created by admin on Mon Mar 31 17:33:23 GMT 2025 , Edited by admin on Mon Mar 31 17:33:23 GMT 2025
CFR 21 CFR 520.1341
Created by admin on Mon Mar 31 17:33:23 GMT 2025 , Edited by admin on Mon Mar 31 17:33:23 GMT 2025
NCI_THESAURUS C776
Created by admin on Mon Mar 31 17:33:23 GMT 2025 , Edited by admin on Mon Mar 31 17:33:23 GMT 2025
WHO-VATC QG03DB02
Created by admin on Mon Mar 31 17:33:23 GMT 2025 , Edited by admin on Mon Mar 31 17:33:23 GMT 2025
WHO-ATC G03FA08
Created by admin on Mon Mar 31 17:33:23 GMT 2025 , Edited by admin on Mon Mar 31 17:33:23 GMT 2025
WHO-ATC L02AB01
Created by admin on Mon Mar 31 17:33:23 GMT 2025 , Edited by admin on Mon Mar 31 17:33:23 GMT 2025
WHO-VATC QG03FA08
Created by admin on Mon Mar 31 17:33:23 GMT 2025 , Edited by admin on Mon Mar 31 17:33:23 GMT 2025
WHO-ATC G03AB01
Created by admin on Mon Mar 31 17:33:23 GMT 2025 , Edited by admin on Mon Mar 31 17:33:23 GMT 2025
WHO-VATC QG03AB01
Created by admin on Mon Mar 31 17:33:23 GMT 2025 , Edited by admin on Mon Mar 31 17:33:23 GMT 2025
NDF-RT N0000175602
Created by admin on Mon Mar 31 17:33:23 GMT 2025 , Edited by admin on Mon Mar 31 17:33:23 GMT 2025
WHO-ATC G03DB02
Created by admin on Mon Mar 31 17:33:23 GMT 2025 , Edited by admin on Mon Mar 31 17:33:23 GMT 2025
WHO-VATC QL02AB01
Created by admin on Mon Mar 31 17:33:23 GMT 2025 , Edited by admin on Mon Mar 31 17:33:23 GMT 2025
NDF-RT N0000011301
Created by admin on Mon Mar 31 17:33:23 GMT 2025 , Edited by admin on Mon Mar 31 17:33:23 GMT 2025
WHO-VATC QG03FB04
Created by admin on Mon Mar 31 17:33:23 GMT 2025 , Edited by admin on Mon Mar 31 17:33:23 GMT 2025
WHO-ATC G03AA04
Created by admin on Mon Mar 31 17:33:23 GMT 2025 , Edited by admin on Mon Mar 31 17:33:23 GMT 2025
WHO-VATC QG03AA04
Created by admin on Mon Mar 31 17:33:23 GMT 2025 , Edited by admin on Mon Mar 31 17:33:23 GMT 2025
Code System Code Type Description
DAILYMED
EA6LD1M70M
Created by admin on Mon Mar 31 17:33:23 GMT 2025 , Edited by admin on Mon Mar 31 17:33:23 GMT 2025
PRIMARY
INN
1529
Created by admin on Mon Mar 31 17:33:23 GMT 2025 , Edited by admin on Mon Mar 31 17:33:23 GMT 2025
PRIMARY
NCI_THESAURUS
C630
Created by admin on Mon Mar 31 17:33:23 GMT 2025 , Edited by admin on Mon Mar 31 17:33:23 GMT 2025
PRIMARY
CHEBI
6722
Created by admin on Mon Mar 31 17:33:23 GMT 2025 , Edited by admin on Mon Mar 31 17:33:23 GMT 2025
PRIMARY
RXCUI
6703
Created by admin on Mon Mar 31 17:33:23 GMT 2025 , Edited by admin on Mon Mar 31 17:33:23 GMT 2025
PRIMARY RxNorm
HSDB
3233
Created by admin on Mon Mar 31 17:33:23 GMT 2025 , Edited by admin on Mon Mar 31 17:33:23 GMT 2025
PRIMARY
FDA UNII
EA6LD1M70M
Created by admin on Mon Mar 31 17:33:23 GMT 2025 , Edited by admin on Mon Mar 31 17:33:23 GMT 2025
PRIMARY
EPA CompTox
DTXSID001009330
Created by admin on Mon Mar 31 17:33:23 GMT 2025 , Edited by admin on Mon Mar 31 17:33:23 GMT 2025
PRIMARY
ChEMBL
CHEMBL1201139
Created by admin on Mon Mar 31 17:33:23 GMT 2025 , Edited by admin on Mon Mar 31 17:33:23 GMT 2025
PRIMARY
WIKIPEDIA
MEGESTROL
Created by admin on Mon Mar 31 17:33:23 GMT 2025 , Edited by admin on Mon Mar 31 17:33:23 GMT 2025
PRIMARY
CAS
3562-63-8
Created by admin on Mon Mar 31 17:33:23 GMT 2025 , Edited by admin on Mon Mar 31 17:33:23 GMT 2025
PRIMARY
EVMPD
SUB08712MIG
Created by admin on Mon Mar 31 17:33:23 GMT 2025 , Edited by admin on Mon Mar 31 17:33:23 GMT 2025
PRIMARY
PUBCHEM
19090
Created by admin on Mon Mar 31 17:33:23 GMT 2025 , Edited by admin on Mon Mar 31 17:33:23 GMT 2025
PRIMARY
ECHA (EC/EINECS)
222-628-6
Created by admin on Mon Mar 31 17:33:23 GMT 2025 , Edited by admin on Mon Mar 31 17:33:23 GMT 2025
PRIMARY
SMS_ID
100000081461
Created by admin on Mon Mar 31 17:33:23 GMT 2025 , Edited by admin on Mon Mar 31 17:33:23 GMT 2025
PRIMARY
MESH
D008535
Created by admin on Mon Mar 31 17:33:23 GMT 2025 , Edited by admin on Mon Mar 31 17:33:23 GMT 2025
PRIMARY